<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5208">
  <stage>Registered</stage>
  <submitdate>23/02/2015</submitdate>
  <approvaldate>23/02/2015</approvaldate>
  <nctid>NCT02534935</nctid>
  <trial_identification>
    <studytitle>Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.</studytitle>
    <scientifictitle>A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To &lt;18 Months Or 18 To &lt;24 Months.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-004400-38</secondaryid>
    <secondaryid>B1971035</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Meningococcal B Disease</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - rLP2086 vaccine
Other interventions - Pediatric HAV vaccine

Experimental: rLP2086 vaccine - Arm stratified by age:
=12 to &lt;18 months and =18 to &lt;24 months

Active Comparator: Control - Arm stratified by age:
=12 to &lt;18 months and =18 to &lt;24 months


Other interventions: rLP2086 vaccine
60 mcg or 120mcg at 0, 2 and 6 months

Other interventions: Pediatric HAV vaccine
0.5-mL dose at months 0 and 6. Normal saline at month 2.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportions of subjects achieving an hSBA titer = LLOQ 1 month after the third vaccination, for each of the 4 primary MnB test strains in healthy toddlers aged 12 to &lt;18 months at study entry.</outcome>
      <timepoint>Month 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportions of subjects achieving an hSBA titer = LLOQ 1 month after the third vaccination, for each of the 4 primary MnB test strains in healthy toddlers aged 18 to &lt;24 months at study entry.</outcome>
      <timepoint>Month 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</outcome>
      <timepoint>Month 0</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</outcome>
      <timepoint>Month 2</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit.</outcome>
      <timepoint>Month 6</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects with at least 1 SAE 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the active SAE collection period.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects with at least 1 medically attended adverse event 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the AE collection period.</outcome>
      <timepoint>Up to 12 Months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects with at least 1 newly diagnosed chronic medical condition 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the AE collection period.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects with at least 1 adverse event 30 days after each vaccination, 30 days after any vaccination and during the vaccination phase.</outcome>
      <timepoint>Up to 7 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</outcome>
      <timepoint>Month 0</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</outcome>
      <timepoint>Month 2</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of subjects reporting at least 1 immediate AE after each vaccination.</outcome>
      <timepoint>Month 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with hSBA titers = LLOQ for each of the 4 primary MnB test strains 1 month after the third vaccination with bivalent rLP2086 in subjects 12 to &lt;24 months.</outcome>
      <timepoint>Month 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with hSBA titers = LLOQ for each of the 4 primary MnB test strains at 1 month after the second vaccination with bivalent rLP2086 and 6, 12, 24, 36, and 48 months after the third vaccination with bivalent rLP2086.</outcome>
      <timepoint>Up to 54 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of subjects with hSBA titers = LLOQ, =1:4, =1:8, =1:16, =1:32, = 1:64, and = 1:128 for each of the 4 primary MnB strains at each applicable blood sampling visit.</outcome>
      <timepoint>Up to 54 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hSBA GMTs for each of the 4 primary test strains at each applicable blood sampling visit.</outcome>
      <timepoint>Up to 54 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female subject aged 12 to &lt;15 months or 18 to &lt;24 months during
             sentinel-cohort enrollment, Or,12 to &lt;24 months during expanded-cohort enrollment.

          -  Subjects must have received all vaccinations in the relevant National Immunization
             Program (NIP) for their age group.

          -  Subject is determined to be in good health by medical history, physical examination,
             and judgment of the investigator.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine
             during Stage 1 of the study.

          -  Contraindication to vaccination with any HAV vaccine or known latex allergy.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  A known or suspected disorder of the immune system that would prevent an immune
             response to the vaccine, such as subjects with congenital or acquired defects in
             B-cell function or those receiving systemic immunosuppressive therapy. Subjects with
             terminal complement deficiency may be included.

          -  History of microbiologically proven disease caused by N meningitidis or Neisseria
             gonorrhoeae.

          -  Significant neurologic disorder or history of seizure (excluding simple febrile
             seizure).

          -  Receipt of any blood products, including immunoglobulin, within 6 months before the
             first study vaccination until the end of Stage 1.

          -  Current chronic use of systemic antibiotics.

          -  Received any investigational drugs, vaccines or devices within 28 days before
             administration of the first study vaccination and/or during study participation.

          -  Any neuroinflammatory or autoimmune condition, including but not limited to transverse
             myelitis, uveitis, optic neuritis, and multiple sclerosis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>31/08/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>396</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>22/02/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>Australian Capital TNSW,SA,VIC,WA</recruitmentstate>
    <hospital>The Canberra Hospital, Paediatric Research and Clinical Trials - Canberra, Garran</hospital>
    <hospital>Australian Clinical Research Network - Maroubra</hospital>
    <hospital>Maroubra Medical Centre - Maroubra</hospital>
    <hospital>Women's And Children's Hospital - North Adelaide</hospital>
    <hospital>Murdoch Children's Research Institute, Royal Children's Hospital Melbourne - Parkville</hospital>
    <hospital>Princess Margaret Hospital for Children - Subiaco</hospital>
    <postcode>2605 - Canberra, Garran</postcode>
    <postcode>2035 - Maroubra</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3010 - Parkville</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Jindrichuv Hradec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 6 - Vokovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Tynec Nad Sazavou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Espoo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Jarvenpaa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Pori</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Debica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Siemianowice Slaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Trzebnica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Worclaw</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the immunogenicity, safety and tolerability of a
      new vaccine that might prevent meningococcal B disease. The study will be conducted in
      healthy toddlers aged between 12 and 24 months.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02534935</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>